#Actinium Therapy in India | Explore Tumblr Posts and Blogs

theboldlycrookedcollector-blog · 5 years

Text

Alpha Emitter Market Size Analysis Report 2024 | Research Cosmos

Alpha Emitter Market Size and Growth Rate:

According to the Research Report published by Research Cosmos ,the global alpha emitter market was estimated at USD 506.50 million in 2018, and it is expected to be valued USD 3302.9 million by 2024,registering a CAGR of 36.6% over the forecast period of 2019-2025.

Browse details of 150 number of pages research report developed on Alpha Emitter Market @

https://www.researchcosmos.com/reports/alpha-emitter-market/22331350

Alpha Emitter Market Growth Drivers and Restraints:

Main drivers contributing to the growth of the market are rising incidences of cardiac & cancer ailments, raised awareness about the potential advantages of targeted alpha therapy and the growing availability of radiopharmaceuticals.

Shorter life of radiopharmaceuticals, need for high capital investment, rigorous regulatory framework and restitution issues are the main factors impacting market growth.

Main drivers contributing to the growth of the alpha emittermarket are rising incidences of cardiac & cancer ailments, raised awareness about the potential advantages of targeted alpha therapy and the growing availability of radiopharmaceuticals.Alpha emitter offers many improvements when compared to beta emitters and photon therapy, thus giving it a frequently favored mode of treatment.North America accounted for the largest share in 2017, followed by Europe and Asia-Pacific.

Alpha Emitter Market Segmentation:

The global alpha emitters market is segmented based on radionuclide type, medical utilization, end user and geography. Based on radionuclide model, the market is divided into Actinium, Astatine (At-211), Bismuth, Bismuth (Bi-212), Lead (Pb-212), Radium and Terbium (Tb-149). Alpha emitter offers many improvements when compared to beta emitters and photon therapy, thus giving it a frequently favored mode of treatment. As a result, this has caught the notice of key companies interested in realizing the market potential. The medical application section is categorized into bone metastasis, endocrine tumors, lymphoma, melanoma, ovarian cancer, pancreatic cancer, and thyroid. Alpha emitter medicine holds a great promise when related to chemotherapy as targeted alpha therapy allows clear discrimination among the healthy cells and cancer cells, and hence are effectively used for the treatment of cancers including ovarian carcinoma, pancreatic cancer etc.

Alpha Emitter Market Geographical Insights:

North America accounted for the largest share in 2017, followed by Europe and Asia-Pacific. Circumstances such as high-end research course in the United States, coupled with high advances in healthcare study and abundant knowledge in cancer research are feeding the growth in North America. In addition to this, the search for alpha emitters is increasing in developing markets such as China and India due to increasing disposable income, raising healthcare standards and reforms in foreign policies. The Asia-Pacific region is expected to grow at a lucrative rate over the forecast period. Growing government initiatives and trends toward the adoption of technologically-advanced outcomes for healthcare are some of the main factors responsible for this growth.

Ask Free Sample of the report @ https://www.researchcosmos.com/request/alpha-emitter-market/22331350

KeyPlayers of the Alpha Emitter Market:

Actinium Pharmaceutical Inc.

Alpha Tau Medical Ltd

Bayer AG

Fusion Pharmaceuticals

IBA Radiopharma Solutions

RadioMedix Inc.

Telix Pharmaceuticals Ltd

For any queries, inquire more @ https://www.researchcosmos.com/inquire/alpha-emitter-market/22331350

About Us:

Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.

Contact:

Kevin Stewart

Global Sales Manager

Research Cosmos

www.researchcosmos.com

Blog: https://acutemarketinsights.com

Blog: https://marketreportsweb.com/

0 notes

stevesmithpoint-blog · 5 years

Text

Global Radiopharmaceuticals Market 2017-2024 |Global Top Players - Cardinal Health Inc., Mallinckrodt Plc., GE Healthcare, Lantheus Medical Imaging Inc., Bayer AG, Bracco Imaging SpA, Eczacibasi-Monrol Nuclear Products, Among others.

Global Radiopharmaceuticals Market, According to Data Bridge Market Research new Market report “By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast To 2024″ is projected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Get Your Sample Report Now! @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiopharmaceuticals-market

Recent Developments:

Recent trends in the radiopharmaceuticals market such as growing disease which targeted cancer therapy, increasing awareness, expanding applications of molecular imaging, technological advancement, increasing trend of radio-labelled peptides and monoclonal antibodies for the diagnosis and treatment of cancer tumors and increasing use of SPECT & PET scans is expected to drive the market in the forecast period 2017 to 2024.

On the other hand, shorter half-life of radiopharmaceuticals, stringent regulatory guidelines and competition from conventional diagnostic procedures are some of the factors which may hinder the growth of radiopharmaceuticals market.

Inquiry Before Buying and Discuss Report Customization with Industry Expert @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiopharmaceuticals-market

Segmentation:

The global radiopharmaceuticals market is segmented based on type, procedural volumes, application, sources, end-user, and geography.

On the basis of type, the radiopharmaceuticals market is sub-segmented into diagnostic and therapeutic radiopharmaceuticals.

On the basis of procedural volumes, the radiopharmaceuticals market is sub-segmented into diagnostic procedures and therapeutic procedures.

On the basis of application, the global radiopharmaceuticals market is sub-segmented into diagnostic application and therapeutic application. Diagnostic application are further sub-segmented into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Single-photon emission computed tomography (SPECT) includes cardiology, lymphoma, thyroid, neurology and others.

On the basis of sources, the global radiopharmaceuticals market is sub-segmented into nuclear reactors and cyclotrons.

On the basis of end user, the global radiopharmaceuticals market is sub-segmented into hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes and others.

Speak to Analyst and Get Free Customized Information about Report @ https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-radiopharmaceuticals-market

Geographical Segmentation:

Based on geography, the market is segmented into five geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.

Request For Details TOC@ https://databridgemarketresearch.com/toc/?dbmr=global-radiopharmaceuticals-market

Company Share Analysis:

The radiopharmaceuticals market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market.

Major Players:

Some of the Major Players Operating in the Global Radiopharmaceuticals Market are:

Cardinal Health Inc.

Mallinckrodt Plc.

GE Healthcare,

Lantheus Medical Imaging Inc.

Bayer AG,

Bracco Imaging SpA,

Eczacibasi-Monrol Nuclear Products,

Nordion Inc.

Advanced Accelerator Applications S.A.

IBA Molecular Imaging,

Covidien Plc,

Positron Corporation,

NTP Radioisotopes Pty. Ltd.

Advanced Medical Isotope Corporation,

Avid Radiopharmaceuticals,

Jubilant Pharma,

Actinium Pharmaceuticals Inc.

AREVA Meds,

Immunomedics Inc.

Merck& Co. Inc.

Navidea,

PETNET Solutions Inc.

Eckert & Ziegler,

Siemens Healthcare,

Positron Corporation,

Among others.

Exclusive News on Global Radiopharmaceuticals Market Report @ https://databridgemarketresearch.com/news/product-launch/global-radiopharmaceuticals-market/

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge Market Research

US: +1-888-387-2818

Email: [email protected]

Website: https://databridgemarketresearch.com

#Radiopharmaceuticals Market #Radiopharmaceuticals Market Analysis

0 notes

khan-kamran81-blog · 6 years

Text

Radiopharmaceuticals Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2024

“Global Radiopharmaceuticals Market –Industry Trends and Forecast to 2025” New Research Report Added to Databridgemarketresearch.com database. The report width Of

Pages : 350 Figures: 60 And Tables: 220 in it.

Report Highlights:

Global Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends and Forecast To 2024

Radiopharmaceuticals Market report also gives an analysis of top players and new comers in industry, competitive landscape, sales, price, revenue, gross margin, market share, market risks, opportunities, market barriers, and challenges key statistics on the market status. Global Industry Trends and Forecast to 2024.

Radiopharmaceuticals Market report provides an outlook for current market value as well as the expected growth of Management Consulting Services during 2018-2025. The whole supply chain of Management Consulting Services has been explained with statistical details with a special emphasis on various upstream and downstream components. The current trends pertaining to the demand, supply, and sales of Management Consulting Services, together with the recent developments have been given here to provide an exhaustive picture of this market.

Market Growth Analysis:

Global Radiopharmaceuticals Market is expected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Market Definition: Radiopharmaceuticals are a group of pharmaceuticals drug which have radioactivity. It can be used as diagnostic and therapeutic agent. Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical area for diagnosis or therapy. The procedures and facilities for the production, use, and storage of radiopharmaceuticals are subject to licensing by national or regional authorities. This licensing includes compliance both with governing radioactive materials and with those regulations governing pharmaceutical preparations. Additional regulations may apply for issues such as transportation or dispensing of radiopharmaceuticals.

Get Free Sample Report@ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiopharmaceuticals-market

Market Segmentation:

The global market is segmented based on type, procedural volumes, application, sources, end-user, and geography.

On the basis of type:-the global radiopharmaceuticals market is sub-segmented into diagnostic and therapeutic radiopharmaceuticals. In 2017, diagnostic radiopharmaceuticals segment dominate the market and is expected to grow at the highest in the forecast period. This is due to the production of MO-99 in the U.S., FDA approvals of radiopharmaceuticals, initiatives of International Atomic Energy Agency (IAEA), new irradiation facility in Germany, installation of PET scanners in India, andgovernment investments in Rest of Asia-Pacific.

On the basis of procedural volumes:- the global radiopharmaceuticals market is sub-segmented into diagnostic procedures and therapeutic procedures. Diagnostic procedures are further sub-segmented into single-photon emission computed tomography (SPECT) radiopharmaceuticals and positron emission tomography (PET) radiopharmaceuticals. Therapeutic procedures are further sub-segmented into beta emitters, alpha emitters and brachy therapy.

On the basis of application:- the global radiopharmaceuticals market is sub-segmented into diagnostic application and therapeutic application. Diagnostic application are further sub-segmented into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Single-photon emission computed tomography (SPECT) includes cardiology, lymphoma, thyroid, neurology and others. Positron emission tomography (PET) includes oncology, cardiology, neurology and others. Therapeutic application is further sub-segmented into thyroid, bone metastasis, lymphoma, endocrine tumours and others.

On the basis of sources:- the global radiopharmaceuticals market is sub-segmented into nuclear reactors and cyclotrons.

On the basis of end user:- the global radiopharmaceuticals market is sub-segmented into hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutesand others. In 2017, hospital segment dominate the market with the highest market share due to accessibility of highly skilled medical practitioners in the radiology departments of hospitals.

Based on geography:-the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others. In 2017, North America is expected to dominate the radiopharmaceuticals market with more than 42.5%market share with a share of 4.7% followed by Europe and Asia-Pacific. However the Asia-Pacific region is expected to grow at the highest CAGR in the forecast period 2017 to 2024. This can be due to the rising demand of PET scanners and high production of radiopharmaceuticals for therapeutic purposes in India, aging population, rising patient awareness, increasing healthcare expenditure in Japan and China, and initiatives by the Australian government.

Customization With Discount Available On This Report, Mail Us@ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiopharmaceuticals-market

Report Describe Strategies About Market Competitors:

Some of the major players operating in the global radiopharmaceuticals market are

Cardinal Health Inc.,

GE Healthcare,

Lantheus Medical Imaging Inc.,

Bayer AG,

Bracco Imaging SpA,

Eczacibasi-Monrol Nuclear Products,

Nordion Inc.,

Advanced Accelerator Applications S.A.,

IBA Molecular Imaging, CovidienPlc,

Positron Corporation,

NTP Radioisotopes Pty. Ltd.,

Advanced Medical Isotope Corporation,

Avid Radiopharmaceuticals,

Jubilant Pharma,

Actinium Pharmaceuticals Inc.,

AREVA Meds,Immunomedics Inc.,

Merck& Co., Inc.,

Navidea,

PETNET Solutions Inc.,

Eckert & Ziegler,

Siemens Healthcare,

Positron Corporation among others.

Key questions answered in the report:

What will the market growth rate of Quantum Computing Market in 2024?

What are the key factors driving the Global Quantum Computing Market?

Who are the key manufacturers in Quantum Computing Market space?

What are the market opportunities, market risk and market overview of the Quantum Computing Market?

What are sales, revenue, and price analysis of top manufacturers of Quantum Computing Market?

Who are the distributors, traders and dealers of Quantum Computing Market?

What are the Quantum Computing Market opportunities and threats faced by the vendors in the Quantum Computing Market industry?

What are sales, revenue, and price analysis by types and applications of Quantum Computing Market?

What are sales, revenue, and price analysis by regions of Quantum Computing Market industry?

Browse Full Information@ https://databridgemarketresearch.com/reports/global-radiopharmaceuticals-market/

About Data Bridge Market Research:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Radiopharmaceuticals Market #Radiopharmaceuticals Market trend #Radiopharmaceuticals Market analysios #Radiopharmaceuticals Market growth #Radiopharmaceuticals Market volume #Radiopharmaceuticals Market outlook

0 notes

nuclearmedicinetherapy · 8 months

Text

Nuclear medicine therapy, also known as radionuclide therapy, is a type of medical treatment that uses radioactive substances to target and destroy cancer cells. Know more at nuclearmedicnetherapy.in

#Nuclear Medicine Therapy in India #Alpha PSMA Therapy in India #lu 177 cancer treatment #Actinium Therapy in India #I-131 MIBG Therapy in India

0 notes

maheshposts-blog1 · 7 years

Text

Market Research Report of Alpha Emitters Market: Global Product Intelligence Industry

Albany/New York Pune/India, April, 2017.

Marketresearchdata.net has added a new report on Global Alpha Emitters Market. The report predicts the market size of Global Alpha Emitters Market is expected to reach XX billion by 2021.

The report covers the analysis of global as well as regional markets of Global Alpha Emitters Market. Moreover, the report gives insights into the factors that affect the global as well as regional performance of the market in the short run and in the long run.

The global market for alpha emitters is currently estimated to be valued at $107 million for the year 2015 and is poised to reach $283 million by the end of 2020. The CAGR during this period of forecast is 21.5%.

Browse full Report visit@

http://marketresearchdata.net/Reports/global-alpha-emitters-market

Alpha emitter radionuclide is considered to be a new approach to tackle cancer and related issues. Alpha emitter provides many advantages when compared to beta emitters and photon therapy, making it an increasingly preferred mode of treatment. As a result, this has caught the attention of major players interested in capitalizing the market potential. Alpha emitters are currently used in the process of Targeted Alpha Therapy (TAT), where in an alpha emitter radionuclide exposes a certain amount of radiation dose to tumor cells, at a very early stage or in the state of metastasis, and destroys the respective cancer cells. In contrast to chemotherapy, TAT allows easy discrimination between the healthy cells and cancer cells. This is helpful in reducing the side effects associated with Chemotherapy. The global market for alpha emitters can be segmented on the basis of radionuclide used – Terbium, Astatine, Bismuth, Actinium, Radium, Lead, Bismuth (Bi-213) and Others; type of medical application – Endocrine tumors, Lymphoma, Bone metastasis, Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid and Others; on the basis of Geography – North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Major drivers contributing to growth of the market are increasing incidences of cardiac & cancer ailments, increased awareness about the potential benefits of targeted alpha therapy and increasing availability of radiopharmaceuticals. However, shorter life of radiopharmaceuticals, need for high capital investment, stringent regulatory framework and reimbursement issues are the major factors impacting market growth.

Table of Content

1. EXECUTIVE SUMMARY

2. INTRODUCTION 2.1 REPORT DESCRIPTION 2.2 RESEARCH METHODOLOGY

3. MARKET OVERVIEW 3.1 MARKET SEGMENTATION 3.2 MARKET DRIVERS 3.1.1 INCREASING INCIDENTS OF CANCER AND CARDIAC AILMENTS 3.1.2 INCREASING SPECT AND PET APPLICATIONS 3.1.3 GROWING PUBLIC AWARENESS FOR POTENTIAL BENEFITS OF NEW TREATMENTS LIKE TARGETED ALPHA THERAPY 3.2 MARKET CONSTRAINTS 3.2.1 SHORT HALF LIFE OF RADIOPHARMACEUTICALS 3.2.2 HIGH CAPITAL INVESTMENT 3.2.3 REGULATORY GUIDELINES 3.2.4. REIMBURSEMENT 3.3 OPPORTUNITIES 3.3.1 INCREASING IMAGING TECHNOLOGIES 3.3.2 POTENTIAL RADIOISOTOPES IN PIPELINE 3.3.3 INCREASING NEUROLOGICAL APPLICATIONS 3.3.4 CYCLOTRON BASED PRODUCTION 3.4 THREATS 3.4.1 SHUTDOWN OF NUCLEAR REACTORS

4. GLOBAL ALPHA EMITTERS MARKET SEGMENTATION 4.1 SEGMENTATION BY TYPE OF RADIONUCLIDE 4.1.1 TERBIUM (Tb-161) 4.1.2 ASTATINE (AT-211) 4.1.3 BISMUTH (BI-212) 4.1.4 ACTINIUM (AC-225) 4.1.5 RADIUM (RA-223) 4.1.6 LEAD (PB-212) 4.1.7 BISMUTH (BI-213) 4.1.8 OTHERS 4.2 SEGMENTATION BY APPLICATION 4.2.1 GLIOMA 4.2.2 MELANOMA 4.2.3 PANCREATIC CANCER 4.2.4 OVARIAN CANCER 4.2.5 THYROID 4.2.6 BONE METASTASIS 4.2.7 LYMPHOMA 4.2.8 ENDOCRINE TUMORS 4.3 SEGMENTATION BY GEOGRAPHY 4.3.1 NORTH AMERICA 4.3.1.1 US 4.3.1.2 CANADA 4.3.1.3 MEXICO 4.3.2 EUROPE 4.3.2.1 GERMANY 4.3.2.2 UK 4.3.2.3 FRANCE 4.3.2.4 SPAIN 4.3.2.5 ITALY 4.3.3 ASIA-PACIFIC 4.3.3.1 INDIA 4.3.3.2 CHINA 4.3.3.3 SOUTH KOREA 4.3.3.4 JAPAN 4.3.4 LATIN AMERICA 4.3.4.1 BRAZIL 4.3.4.2 CHILE 4.3.4.3 ARGENTINA 4.3.5 MIDDLE EAST & AFRICA

5. COMPETITIVE LANDSCAPE 5.1 MERGERS, ACQUISITIONS & SPIN OFFS 5.2 COLLABORATIONS 5.3 PRODUCT LAUNCHES

6. COMPANY PROFILES 6.1 IBA GROUP 6.2 LANTHEUS MEDICAL IMAGING 6.3 TRIAD ISOTOPES 6.4 SIEMENS HEALTHCARE (PETNET SOLUTIONS) 6.5 NTP RADIOISOTOPES 6.6 ACTINIUM PHARMACEUTICALS 6.7 BAYER HEALTHCARE

To make an enquiry about report visit:

http://marketresearchdata.net/Reports/MakeEnquiryRequest/17443.html

Reasons to buy this report: 1) Deep insights and comprehensive analysis of global and regional markets 2) complete coverage of key product types and application segments and their sub-segments through geographies and world market 3) Deep dive into the market share and recent developments of the key players in the industry. 4) Analysis and presentation of evolving market trends, patterns, technological advancements 5) Presentation of market dynamics and factors bearing control over the global and regional markets. 6) Competitive landscapes and insights 7) Opportunity mapping in terms of product developments, research and developments and technological advancements.

To know more about us Visit: http://marketresearchdata.net/Welcome/About.html Reasons to choose marketresearchdata.net 1) 24X7 sales support and free analyst time for post purchase queries. 2) Exclusive support from the analysts and industry experts possessing experience over 5 years in the industry 3) Long term relationship management and exclusivity benefits for our clients

To make sample request for report visit: http://marketresearchdata.net/Reports/MakeSampleRequest/17443.html Contact Us: USA/Canada Toll Free: +18006380796 Rest of the World: +919765091631 Email: [email protected] website: www.marketresearchdata.net

#Alpha Emitters Market size #Alpha Emitters Market trends #Alpha Emitters Market analysis #Alpha Emitters Market share #Alpha Emitters Market forecast

0 notes